|
1. Maximizing Treatment Outcome in OCD
IRB# 5188
Principal Investigator: Dr. H. Blair Simpson
To schedule a confidential screening, contact:
Jose Hernandez #212-543-5367 or Jessica McCarthy #212-543-5380
Overview of Study:
This study compares the effectiveness of two proven treatment strategies for OCD patients who are currently on a serotonin reuptake inhibitor (SRI, i.e., clomipramine, fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, or escitalopram) but still have residual symptoms. Participants remain on their current medication and receive either cognitive-behavioral therapy (CBT) consisting of exposure and ritual prevention or an additional medication (risperidone). The goal is to compare these two augmentation strategies, each of which has been found effective in prior studies. All treatment is at no charge. Note: Patients who do not improve after 8.5 weeks of treatment will be offered at no-cost the treatment they did not initially receive (either the CBT or the add-on medication).
Key Eligibility Criteria:
18-70 years; both genders
Key Inclusion Criteria:
- OCD is the primary problem
- On a stable dose of a serotonin reuptake inhibitor
Key Exclusion Criteria:
- Medical or psychiatric conditions that would make study participation hazardous
- Patients who have already had an adequate trial of these augmentation strategies while on a serotonin reuptake inhibitor
Who is this study for?
OCD patients on medications who still have bothersome symptoms and who have not previously received an adequate trial of these proven augmentation strategies.
2. Imaging the Serotonin System in OCD
IRB#5494R
P.I. Dr. H. Blair Simpson
To schedule a confidential screening, contact:
Jose Hernandez #212-543-5367 or Dr. Michael Maher #212-543-5370
Overview of Study:
The study examines whether the brain serotonin system is different in patients with obsessive-compulsive disorder (OCD) than in those without OCD. One of the brain serotonin receptors will be measured using a standard imaging procedure called positron emission tomography (PET). An anatomical picture of the brain using magnetic resonance imaging (MRI) is also done. Subjects are compensated $500 for their participation and offered three months of OCD treatment at no cost to them.
Eligibility:
18-55 years, both genders
Key Inclusion Criteria:
- OCD is the primary problem.
- Not currently on psychiatric medications.
Key Exclusion Criteria:
- Current medical or neurological problem that would make participation hazardous
Who is this study for?
For people with OCD who are not on psychiatric medications and who would like to help us answer the scientific question of whether their brain differs in this way from people without OCD.
|
